| 前收市價 | 0.1300 |
| 開市 | 0.3000 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 1.50 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 0.2500 - 0.3000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1.98k |
InvestorPlaceThe Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Do you have any penny stocks in your portfolio? If you don’t, you might want to consider it with any speculative money sitting on the sidelines. Penny stocks are usually those of small-cap, or even micro-cap companies with little revenue and are frequently not profitable. That’s enough to steer away many investors. But a little research can help you sort out the companies with little hope of growth versus those that may be a diamond in the rough. Remember, companies such as Amazon (NASDAQ:AMZN)
BenzingaGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement to develop and commercialize seralutinib. This global collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate the development of pulmonary hypertension associated with interstitial lung disease (PH-ILD). “Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD,
- Reuters
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
